高级检索
当前位置: 首页 > 详情页

Renal Kallikrein Activation and Renoprotection after Dual Blockade of Renin-Angiotensin System in Diet-Induced Diabetic Nephropathy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Center for Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, China [2]Molecular Endocrinology and Toxicology Laboratory, Department of Biology, Hong Kong Baptist University, Kowloon 999077, Hong Kong [3]Department of Endocrinology, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou 510120, China
出处:
ISSN:

摘要:
Purpose. The objective of this study is to investigate the effect of dual blockage of renin-angiotensin system(RAS) on renal kallikrein expression and inflammatory response in diabetic nephropathy (DN). Methods. Rats were randomly divided into 5 groups with 10 rats in each group: normal control; DN model induced by high fat and high sucrose diets; and DN treated with either benazepril 10 mg/kg/d, irbesartan 30 mg/kg/d, or both. After 8-week treatment, we examined changes in the kidney histopathology, function and immunohistochemical stain of kallikrein, macrophage marker CD68, and profibrotic markers transforming growth factor-(TGF-) beta and alpha-smooth muscle action (SMA). Results. DN rats showed enlarged kidneys with glomerulosclerosis, interstitial chronic inflammation and fibrosis, and proteinuria. All the pathological damage and functional impairments were improved after the RAS blockades (all P < 0.05). Compared with monotherapy, combined treatment further alleviated the kidney impairments in parallel to increased tubular immunoreactivity for kallikrein and decreased immunopositive cells for CD68, TGF-beta, and alpha-SMA. Conclusion. The renoprotective effects of the dual RAS blockade in diabetic nephropathy may be attributed to improved tubular kallikrein expression and interstitial inflammatory response.

基金:

基金编号: KY2011002 81270934

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 4 区 内分泌学与代谢 4 区 医学:研究与实验
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 内分泌学与代谢 3 区 医学:研究与实验
JCR分区:
出版当年[2013]版:
Q4 ENDOCRINOLOGY & METABOLISM Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q2 ENDOCRINOLOGY & METABOLISM Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Center for Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin 541004, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号